Sugi Predict

Sugi Predict / Compounds / SCHEMBL927414

SCHEMBL927414

SCHEMBL927414

COCCc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5cccnc5)cc4c32)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 8/20 0.56
▸ ATM Q13315 11/20 0.51
▸ ATR Q13535 5/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ MTOR P42345 5/20 0.48
▸ PIK3CB P42338 4/20 0.48
▸ PIK3CG P48736 4/20 0.48
▸ PIK3CA P42336 3/20 0.48
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ FECH P22830 1/20 0.41
▸ CLK1 P49759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL928363 0.88 PIK3CD (0.61) PIK3CDATMATRKCNH2MTOR
SCHEMBL930515 0.87 PIK3CD (0.57) PIK3CDATMATRMTORPIK3CB
SCHEMBL927258 0.84 ATM (0.54) PIK3CDATMATRKCNH2MTOR
SCHEMBL927875 0.84 ATM (0.58) PIK3CDATMATRKCNH2MTOR
SCHEMBL928008 0.81 PIK3CD (0.62) PIK3CDATMATRKCNH2MTOR
SCHEMBL930080 0.80 ATM (0.53) PIK3CDATMATRKCNH2MTOR
SCHEMBL9905459 0.80 ATM (0.56) PIK3CDATMATRKCNH2MTOR
SCHEMBL994161 0.80 PIK3CD (0.55) PIK3CDATMATRMTORPIK3CB
SCHEMBL994420 0.80 PIK3CD (0.57) PIK3CDATMATRKCNH2MTOR
SCHEMBL9905296 0.79 MTOR (0.56) PIK3CDATMATRKCNH2MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 — — EP claimed
US-7994170-B2 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2011-08-09 — — US claimed
EP-2292617-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors Novartis AG (CH) 2011-03-09 — — EP claimed
EP-2270008-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors Novartis AG (CH) 2011-01-05 — — EP claimed
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-04 — — US claimed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US claimed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP claimed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO claimed
US-9370508-B2 Imidazoquinolines as dual lipid kinase and mTOR inhibitors NOVARTIS AG (CH) 2016-06-21 — — US disclosed
EP-2624831-A1 PHARMACEUTICAL COMBINATIONS Novartis AG (CH) 2013-08-14 — — EP disclosed
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS NOVARTIS AG (CH) 2013-07-11 — — US disclosed
US-8431592-B2 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2013-04-30 — — US disclosed
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes NOVARTIS AG (CH) 2012-11-08 — — US disclosed
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 — — EP disclosed
US-7667039-B2 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2010-02-23 — — US disclosed
EP-2129379-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS Novartis AG (CH) 2009-12-09 — — EP disclosed
WO-2008103636-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS NOVARTIS AG (CH) 2008-08-28 — — WO disclosed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US disclosed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP disclosed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS PDPK1, PI4KA, PIP4K2A PIK3CD 9/4885ATM 1665/4885ATR 3330/4885
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS MTOR, RICTOR, PIK3CA PIK3CD 4/4885ATM 545/4885ATR 725/4885
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes KDR, FLT4, TEK PIK3CD 1413/4885ATM 3879/4885ATR 3288/4885
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors PDPK1, PI4KA, PIP4K2A PIK3CD 9/4885ATM 1665/4885ATR 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.